FdaApplication
NDA 213716
Identifiers
- fda_app_no: NDA213716
Properties
| Property | Value |
|---|---|
| applicant_name | AURINIA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-01-22 |
Revenue by product
LUPKYNIS
| Period | Revenue |
|---|---|
| Q2 2026 | $79.4M |
| Q1 2026 | $73.6M |
| Q3 2025 | $70.6M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LUPKYNIS | VOCLOSPORIN | 7.9MG | CAPSULE;ORAL |
1 product